Overcoming soluble target interference in an anti-therapeutic antibody screening assay for an antibody-drug conjugate therapeutic

Bioanalysis

Volumn 4, Issue 16, 2012, Pages 2013-2026

  Carrasco Triguero, Montserrat ^a   Mahood, Connie ^a   Milojic Blair, Marija ^a   Amaya, Caroline ^a   Ruppel, Jane ^a   Hong, Kyu ^a   Yi, Joo Hee ^a   Kaur, Surinder ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CA 125 ANTIGEN; MONOMETHYLAURISTATIN E MONOCLONAL ANTIBODY CONJUGATE; UNCLASSIFIED DRUG; WHEAT GERM AGGLUTININ;

ANTIBODY DETECTION; ARTICLE; BINDING AFFINITY; BINDING COMPETITION; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS REACTION; DRUG CONJUGATION; FALSE POSITIVE RESULT; FEMALE; HUMAN; IMMUNOASSAY; IMMUNOGENICITY; MOLECULAR INTERACTION; PROCESS DEVELOPMENT; SENSITIVITY AND SPECIFICITY; VALIDATION STUDY;

ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; BIOLOGICAL AGENTS; CA-125 ANTIGEN; DRUG CARRIERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FALSE POSITIVE REACTIONS; HUMANS; IMMUNOASSAY; IMMUNOCONJUGATES; MACACA FASCICULARIS; MEMBRANE PROTEINS; NEOPLASMS; SENSITIVITY AND SPECIFICITY; SOLUBILITY; WHEAT GERM AGGLUTININS;

EID: 84866096234     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.12.165     Document Type: Article

References (34)

1. Casadevall N, Nataf J, Viron B et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N. Engl. J. Med. 346(7), 469-475 (2002
2. Shankar G, Shores E, Wagner C, Mire-Sluis A. Scientific and regulatory considerations on the immunogenicity of biologics. Trends Biotechnology 24(6), 274-280 (2006
3. Mire-Sluis AR, Barrett YC, Devanarayan V et al. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J. Immunological Methods 289(1-2), 1-16 (2004
4. Wadhwa M, Thorpe R. Unwanted immunogenicity: Lessons learned and future challenges. Bioanalysis 2(6), 1073-1084 (2010
5. Patton A, Mullenix MC, Swanson SJ, Koren E. An acid dissociation bridging ELISA for detection of antibodies directed against therapeutic proteins in the presence of antigen. J. Immunol. Methods 304(1-2), 189-195 (2005
6. Swann PG, Tolnay M, Muthukkumar S, Shapiro MA, Rellahan BL, Clouse KA. Considerations for the development of therapeutic monoclonal antibodies. Curr. Opin. Immunol. 20(4), 493-499 (2008
7. Mikulskis A, Yeung D, Subramanyam M, Amaravadi L. Solution ELISA as a platform of choice for development of robust, drug tolerant immunogenicity assays in support of drug development. J. Immunol. Methods 365(1-2), 38-49 (2011
8. Maia M, Lowe J, Wakshull E, Quarmby V. A novel strategy for elimination of soluble-ligand interference in immunogenicity assays. Presented at: AAPS National Biotechnology Conference. Seattle, WA, USA 21-24 June 2009.
9. Zhong ZD, Dinnogen S, Hokom M et al. Identification and inhibition of drug target interference in immunogenicity assays. J. Immunol. Methods 355(1-2), 21-28 (2010
10. Chen Y, Clark S, Wong T et al. Armed antibodies targeting the mucin repeats of the ovarian cancer antigen, MUC16, are highly efficacious in animal tumor models. Cancer Res. 67(10), 4924-4932 (2007
11. Junutula JR, Raab H, Clark S et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat. Biotechnol. 26(8), 925-932 (2008
12. O'Brien TJ, Beard JB, Underwood LJ, Dennis RA, Santin AD, York L. The CA 125 gene: An extracellular superstructure dominated by repeat sequences. Tumour Biology: J. Intl Soc. Oncodevelopmental Biol. Med. 22(6), 348-366 (2001
13. Yin BW, Lloyd KO. Molecular cloning of the CA125 ovarian cancer antigen: Identification as a new mucin, MUC16. J. Biol. Chem. 276(29), 27371-27375 (2001
14. Kui Wong N, Easton RL, Panico M et al. Characterization of the oligosaccharides associated with the human ovarian tumor marker CA125. J. Biol. Chem. 278(31), 28619-28634 (2003
15. Bast RC Jr, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC. Reactivity of a monoclonal antibody with human ovarian carcinoma. J. Clin. Investig. 68(5), 1331-1337 (1981
16. Bast RC Jr, Xu FJ, Yu YH, Barnhill S, Zhang Z, Mills GB. CA 125: The past and the future. Int. J. Biological Markers 13(4), 179-187 (1998
17. Sturgeon CM, Duffy MJ, Stenman UH et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin. Chem. 54(12), e11-79 (2008
18. Shankar G, Devanarayan V, Amaravadi L et al. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J. Pharm. Biomed. Anal. 48(5), 1267-1281 (2008
19. Warren DJ, Nustad K, Beard JB, O'Brien TJ. Expression and epitope characterization of a recombinant CA 125 repeat: Fourth report from the ISOBM TD-1 workshop. Tumour Biol. 30(2), 51-60 (2009
20. Sharon N. Lectin-carbohydrate complexes of plants and animals: An atomic view. Trends Biochem. Sci. 18(6), 221-226 (1993
21. Gubbels JA, Belisle J, Onda M et al. Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol. Cancer 5(1), 50 (2006
22. Hongsachart P, Huang-Liu R, Sinchaikul S et al. Glycoproteomic analysis of WGA-bound glycoprotein biomarkers in sera from patients with lung adenocarcinoma. Electrophoresis 30(7), 1206-1220 (2009
23. Venegas M, Liu L, Lovell L et al. Purification and immunochemical characterization of ascitic fluid glycoproteins containing certain tumor-associated and blood group antigen markers. Glycoconjugate J. 6(4), 511-524 (1989
24. Chrispeels MJ, Raikhel N.V. Lectins, lectin genes, and their role in plant defense. Plant Cell 3(1), 1-9 (1991
25. Klein A, Michalski JC, Morelle W. Modifications of human total serum N-glycome during liver fibrosis-cirrhosis, is it all about immunoglobulins? Proteomics. Clin. Appl. 4(4), 372-378 (2010
26. Yamaguchi Y, Takahashi N, Kato K. Molecular interactions: Antibody structures. In: Comprehensive Glycoscience. Kamerling JP (Ed.). Elsevier Ltd, Oxford, UK, 745-763 (2007
27. Burton D.R. Structure and function of antibodies. In: Molecular Genetics of Immunoglobulin. Calabi F, Neuberger MS (Eds). Elsevier, Amsterdam, New York, Oxford, 1-50 (1987
28. Suzuki N, Lee YC. Site-specific N-glycosylation of chicken serum IgG. Glycobiology 14(3), 275-292 (2004
29. Riedinger JM, Wafflart J, Ricolleau G et al. CA 125 half-life and CA 125 nadir during induction chemotherapy are independent predictors of epithelial ovarian cancer outcome: results of a French multicentric study. Ann. Oncol. 17(8), 1234-1238 (2006
30. US FDA. Guidance for Industry: Assay Development for Immunogenicity Testing of Therapeutic Proteins. US Department of Health and Human Services Food and Drug Administration (2009
31. Garofolo F, Rocci ML Jr, Dumont I et al. 2011 White paper on recent issues in bioanalysis and regulatory findings from audits and inspections. Bioanalysis 3(18), 2081-2096 (2011
32. Gebauer M, Skerra A. Engineered protein scaffolds as next-generation antibody therapeutics. Curr. Opin. Chem. Biol. 13(3), 245-255 (2009
33. Lipovsek D. Adnectins: engineered target-binding protein therapeutics. Protein Eng. Des. Sel. 24(1-2), 3-9 (2011
34. Mairal T, Ozalp VC, Lozano Sanchez P, Mir M, Katakis I, O'Sullivan CK. Aptamers: Molecular tools for analytical applications. Anal. Bioanal. Chem. 390(4), 989-1007 (2008